Skip to main content

Table 2 Cost-utility ratios of providing RSV immunoprophylaxis to infants by risk group and by annual hospitalizations in children aged 0–2 years old (a)

From: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Risk Group Annual hospitalizations in children aged 0–2 years
2700 2945 3200
Cost per DALY including asthma Cost per DALY including asthma Cost per DALY including asthma
CHD $223,687 $218,968 $214,347
CLD $303,658 $287,057 $268,242
<29 $246,594 $226,900 $208,765
29–32 $369,551 $347,593 $327,141
33–36 $1,211,273 $1,149,584 $1,092,860
No risk $3,217,414 $3,023,294 $2,849,644
  1. acost-effectiveness threshold is $105,986 per averted DALY